Article
Oncology
Magali Merrien, Agata M. Wasik, Christopher M. Melen, Mohammad Hamdy Abdelrazak Morsy, Kristina Sonnevi, Henna-Riikka Junlen, Birger Christensson, Bjorn E. Wahlin, Birgitta Sander
Summary: Most lymphoma patients relapse after therapy due to hidden malignant cells in tissues protected by the microenvironment. The study focuses on the interaction between the biolipid 2-arachidonoylglycerol and the chemokine CXCL12 in lymphoma cell migration. The study demonstrates that 2-arachidonoylglycerol induces migration of B-lymphoma cells and affects the signaling pathways activated by CXCL12. The results suggest the previously unrecognized role of 2-arachidonoylglycerol in lymphoma cell mobilization.
Article
Cell Biology
Xiao-Hui Wang, Shu-Feng Zhang, Hai-Ying Wu, Jian Gao, Xu-Hui Wang, Tian-Hui Gao
Summary: Our study reveals that the expression of SOX17 is repressed in neuroblastoma tissues and cells, and that SOX17 suppresses NB tumor formation and proliferation through inhibition of the CXCL12/CXCR4 signaling pathway.
CELLULAR SIGNALLING
(2021)
Article
Medicine, Research & Experimental
Mei Zheng, Sang Ho Oh, Nahyun Choi, Yong Jin Choi, Jino Kim, Jong-Hyuk Sung
Summary: This study reveals that CXCL12 inhibits hair growth through the CXCR4/STAT signaling pathway, and inhibitors of the CXCL12/CXCR4 pathway show promise as a treatment option for hair growth.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Tomokatsu Kato, Yoichi Matsuo, Goro Ueda, Hiromichi Murase, Yoshinaga Aoyama, Kan Omi, Yuichi Hayashi, Hiroyuki Imafuji, Kenta Saito, Mamoru Morimoto, Ryo Ogawa, Hiroki Takahashi, Shuji Takiguchi
Summary: The study found that CXCR4 is highly expressed in radiation-resistant PaCa cells, and the CXCL12/CXCR4 axis may be involved in the radiation resistance of PaCa. Treatment with a CXCR4 antagonist can suppress the invasion ability of radiation-resistant PaCa cells, aiding in the inhibition of cell colonization.
Article
Cell Biology
Kathryn E. Luker, Gary D. Luker
Summary: This study reveals the regulation of PKM2 and cellular metabolism by CXCL12 signaling through CXCR4 and ACKR3, leading to the dissociation of PKM2 from beta-arrestin 2 and a shift in its oligomerization state.
Article
Oncology
Nicholas R. Anderson, Vipul Sheth, Hui Li, Mason W. Harris, Shaowei Qiu, David K. Crossman, Harish Kumar, Puneet Agarwal, Takashi Nagasawa, Andrew J. Paterson, Robert S. Welner, Ravi Bhatia
Summary: Using a mouse model of FLT3-ITD AML, researchers found that FLT3-ITD AML LSC were enriched within the ST-HSC population and had increased expression of CXCR4. Deletion of CXCL12 from the microenvironment enhanced targeting of AML cells by Flt3-TKI plus chemotherapy treatment, including enhanced LSC targeting. Inhibition of p38 signaling reduced the maintenance of Flt3-ITD AML LSC and enhanced their sensitivity to treatment.
Article
Multidisciplinary Sciences
Xue Yan Cui, Geir Erland Tjonnfjord, Sandip M. Kanse, Anders Erik Astrup Dahm, Nina Iversen, Christiane Filion Myklebust, Ling Sun, Zhong Xing Jiang, Thor Ueland, James J. Campbell, Mitchell Ho, Per Morten Sandset
Summary: Plasma TFPI levels are higher in CLL patients compared to healthy controls, especially in those with advanced disease. TFPI enhances CXCL12-mediated migration of CLL cells through increased expression of the CXCR7 receptor. TFPI, which co-localizes with GPC3, plays a crucial role in regulating CXCR7 expression and TEM.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Ehsan Gharib, Vanessa Veilleux, Luc H. Boudreau, Nicolas Pichaud, Gilles A. Robichaud
Summary: Inflammation and platelets promote cancer malignancy. Platelet-derived microparticles (PMPs) induce metabolic plasticity and disease progression in chronic lymphocytic leukemia (CLL). PMPs enhance CLL tumor growth and invasiveness through mitochondrial internalization and OXPHOS stimulation, as well as increase resistance to chemotherapy drugs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Delphine Tardivon, Mateusz Antoszewski, Nadine Zangger, Marianne Nkosi, Jessica Sordet-Dessimoz, Rudi Hendriks, Ute Koch, Freddy Radtke
Summary: NOTCH1 gain-of-function mutations are common in B-cell chronic lymphocytic leukemia, and play a role in disease progression and chemotherapy resistance. In an in vivo mouse model of CLL, activation of Notch signaling facilitated disease initiation and promoted CLL cell proliferation and disease progression, while inhibition of Notch signaling delayed disease induction.
Article
Cell Biology
Liam A. Ridge, Dania Kewbank, Dagmar Schuetz, Ralf Stumm, Peter J. Scambler, Sarah Ivins
Summary: The study shows that CXCL12 signaling through its receptor CXCR4 plays distinct roles in different stages of SLV development, guiding cellular distribution and regulating cell proliferation. The atypical chemokine receptor CXCR7 may have a role in regulating ligand bioavailability during SLV morphogenesis.
Article
Immunology
Meng Zhang, Yi Liu, Jing Chen, Lei Chen, Li Zhang, Xianguo Chen, Zongyao Hao, Chaozhao Liang
Summary: This study identified highly expressed factors in the prostate tissues of CNP mice and found that targeting the CXCL12/CXCR4 axis could alleviate inflammation. The study also explored the influence of this axis on downstream signaling pathways.
JOURNAL OF INFLAMMATION RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Kristan V. Piroeva, Charlotte Mcdonald, Charalampos Xanthopoulos, Chelsea Fox, Christopher T. Clarkson, Jan-Philipp Mallm, Yevhen Vainshtein, Luminita Ruje, Lara C. Klett, Stephan Stilgenbauer, Daniel Mertens, Efterpi Kostareli, Karsten Rippe, Vladimir B. Teif
Summary: This study compared the nucleosome positions in chronic lymphocytic leukemia (CLL) patients and healthy individuals, and found significant changes in nucleosome positioning in CLL. The spacing between nucleosomes was shortened, and changes in nucleosome occupancy were linked to chromatin remodeling and reduced DNA methylation. Nucleosome positioning can be used to classify CLL subtypes and monitor disease progression.
Article
Clinical Neurology
I-Tsang Chiang, Yu-Chang Liu, Hua-Shan Liu, Ahmed Atef Ahmed Ali, Szu-Yi Chou, Tsung- Hsu, Fei-Ting Hsu
Summary: Our study found that regorafenib can enhance the efficacy of temozolomide against glioblastoma by inhibiting the CXCL12/CXCR4/ERK/NF-κB signaling pathway. Additionally, regorafenib can sensitize glioblastoma cells to temozolomide and reduce tumor size and prolong survival in animal models.
Article
Oncology
Wenjie Zhang, Jinlan Long, Peixia Tang, Kaili Chen, Guangyao Guo, Zezhong Yu, Jie Lin, Liping Liu, Rong Zhan, Zhenshu Xu
Summary: In this study, the role of synaptotagmin 7 (SYT7) in chronic lymphocytic leukemia (CLL) was investigated. It was found that SYT7 promoted CLL development by inhibiting SYVN1-mediated KNTC1 ubiquitination. Knockdown of SYT7 inhibited malignant behaviors of CLL cells, while overexpression of SYT7 promoted CLL development.
BIOMARKER RESEARCH
(2023)
Article
Immunology
Paola Antonello, Diego U. Pizzagalli, Mathilde Foglierini, Serena Melgrati, Egle Radice, Sylvia Thelen, Marcus Thelen
Summary: Chemotaxis is an essential process in tumors metastasis, and in this study, ACKR3 was found to control the migration of lymphoma cells in response to CXCL12. The interaction between LTB4 and CXCL12 enhances the migration of lymphoma cells, providing a novel mechanism for cell-to-cell-induced migration.
FRONTIERS IN IMMUNOLOGY
(2023)